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Abstract
Clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR-
associated system (Cas) is a system that 
provides immunity to most prokaryotic 
organisms against viral attacks and other 
foreign bodies. CRISPR systems consist of a 
scissor-like protein called Cas9 and a genetic 
GPS guide “The guide RNA”. However, 
researchers have reoriented and repurposed 
the primordial immune system to precisely 
manipulate genomes in most organisms by 
introducing DNA double-strand breaks at 
specific genome locations to introduce specific 
DNA modifications. More applications of 
CRISPR have arisen since its discovery, from 
disabling parasites to correcting mutations 
and improving crop yields. This review was 
conceived as a guide to CRISPR technology, 
from its discovery to the latest breakthroughs. 
It is hoped that this study will provide a 
general-based view for this life changing 
technology, inspiring scientists to go further 
with CRISPR in the sake of a better life. 
Key words: CRISPR/Cas9; DNA; RNA; 
genome engineering; bacteria; virus
Introduction
In the early 20th century, physicians 
and chemists unlocked the secrets of 
the atom, changing the world forever. 
But life remained a profound mystery. 
Inheritance remained one of life’s 
deepest secrets. Everyone knew that 
traits, such as the shape of a pea pod, 
or eye and hair colour, are passed on 
from generation to generation. But 
no one knew how such information 
was stored or transmitted. Scientists 
were convinced that there had to be a 
biological molecule at the heart of the 
process, and that this molecule had 
to have certain special qualities. The 
challenge of solving this mysterious 
“secret of life” and, furthermore, 
finding a way to edit it, now known 
as genetic engineering, was taken up 
(Doudna and Gersbach, 2015).
With the revolutionary discovery 
of DNA, scientists tried to manipulate 
it using different techniques like 
radiation and chemicals, causing 
random mutations in the DNA (1960s). 
In the 1970s, scientists discovered new 
technologies for sequencing, copying, 
and manipulating DNA, and they started 
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using them on many different cells for 
research and medical reasons (Pray, 
2008).
These technologies for manipulating 
DNA were truly promising and have 
enabled advances in biology ever since 
the discovery of the DNA double helix. 
But until recently, it has been very 
difficult to rapidly obtain experimental 
results, as these techniques take a lot of 
time and effort and sometimes they were 
inefficient. Furthermore, introducing 
site-specific modifications in the genomes 
of cells and organisms remained elusive. 
Early approaches relied on the principle 
of the site-specific recognition of DNA. 
More recently, the site-directed zinc 
finger nucleases (ZFNs) and TAL effector 
nucleases (TALENs) were developed 
using the principles of DNA protein 
recognition. However, difficulties of 
protein design, synthesis and validation 
remained a barrier to widespread 
adoption of these engineered nucleases 
for routine use (Doudna and Gersbach, 
2015).
However, all this changed with 
the emergence of a new technology; 
CRISPR, short for “clusters of regularly 
interspaced short palindromic repeats”. 
It was as though someone has pressed 
fast-forward on the gene-editing field. 
CRISPR is a simple tool that scientists 
can wield to snip and edit DNA, thus 
accelerating the pace of advancements 
that could lead to treating and preventing 




The short answer is that the CRISPR 
technology is a revolutionary new class 
of molecular tools that scientists can use 
to make changes in any kind of genetic 
material. It involves the precise targeting, 
cutting and pasting of DNA in cells. 
CRISPR systems are the simplest yet 
most powerful methods scientists have 
ever had to alter any DNA sequence on 
Earth, including human DNA.
The long answer is that CRISPRs are 
repeating sequences found in the genetic 
code of bacteria. They are interspersed 
with ‘spacers’ - unique stretches of DNA 
that the bacteria grab from invading 
viruses, creating a genetic record of their 
malicious encounters. CRISPR systems 
consist of a scissor-like protein called 
Cas9 and a genetic GPS guide “The guide 
RNA= gRNA”. Such systems inspired by 
nature and engineered by researchers 
naturally evolved across the bacterial 
kingdom as a way to foil attacks by 
viruses and other foreign bodies. But 
researchers reoriented and repurposed 
that primordial immune system to 
precisely manipulate genomes (Doudna 
and Gersbach, 2015).
Figure 1. A brief history of CRISPR (Ledford, 
2015)
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How it was first discovered?
Years ago, sequences of clustered, 
regularly interspaced short palindromic 
repeats (CRISPRs) were found 
disseminated in the genomes of numerous 
bacteria. In 1987, the first description of a 
CRISPR array was made by researchers 
who found repeats of multiple base pairs 
(bp), interspersed by bp non-repeating 
spacer sequences in Escherichia coli. 
In 1995, similar CRISPR arrays were 
found in Mycobacterium tuberculosis, 
Haloferax mediterranei, and other bacteria 
and archaea. Several hypotheses for the 
function of CRISPRs have been proposed. 
However, their function as a safeguard 
and defence system against viruses was 
not highlighted until 2007, when several 
research groups reported that the spacer 
sequences often contained parts of 
phage-derived DNA or plasmids, and 
they proposed that CRISPR uses these 
extra-chromosomal agents to mediate 
immunity against infection. Other 
researchers also reported a negative 
correlation between the number of 
CRISPR spacers in the genome of bacteria 
and their sensitivity to phage infection. 
Several years later, scientists confirmed 
this hypothesis experimentally by 
showing that after phage invasion, new 
spacers were acquired that conferred 
resistance against the phage (Sorek, 2008). 
In 2012, as part of a basic research 
project on how bacteria fight viral 
infections, it was invented a new 
technology for editing the genome using 
the CRISPR-Cas9 (CRISPR Associated 
Proteins 9) system (Doudna and 
Gersbach, 2015) (Figure 1).
How it works?  
(The CRISPR lexicon) 
CRISPR loci are found solely in the 
genome of archea and bacteria, they 
contain the CRISPR arrays including 
the leader sequence, as the sequence 
that contains hundreds of nucleotides 
and where the transcription of the array 
CRISPR starts. Researchers found that a 
CRISPR loci lacking the leader sequence 
is unable to incorporate new spacers and 
to execute the CRISPR-Expression and 
interference (Sinan Al-Attar, 2011).
The associated Cas genes
The CRISPR array: sequences of 
clustered (cluster means groups), 
regularly interspaced palindromic 
(having the property of reading the same 
forwards as backwards) repeats found in 
the genome of many bacteria and almost 
all archea.
These arrays are composed of direct 
repeats “short palindromic repeats” 
that are separated by similarly sized 
non-repetitive spacers “protospacers” 
originating from either phages or 
plasmids and comprise the prokaryotic 
“immunological memory” (Sorek, 2008). 
CRISPR associated proteins (Cas): 
enzymes having a role in the mediated 
CRISPR resistance, i.e., nucleases, 
helicases, integrases and polymerases. 
These play a role in the addition and 
suppression of new spacers, processing 
of the CRISPR-Transcripts and mediation 
of other CRISPR-defence processes 
(Sinan Al-Attar, 2011). The Cas9 is an 
endonuclease found in CRISPR type II 
and guided by two RNA (Doudna and 
Gersbach, 2015).
CRISPR RNA (crRNA) is generated 
from the CRISPR loci. Their function is 
to guide Cas proteins to silence invading 
nucleic acids.
The CRISPR array is transcribed to 
make the precursor-CRISPR-RNA (pre-
crRNA). Under the co-processing of 
transcript-activating crRNA (tracrRNA) 
and RNas III, the pre-crRNA matures 
and becomes crRNA. The dual tracrRNA 
crRNA with the Cas9 then form a 
complex to cleave site-specific target 
DNA (Chylinski et al., 2013). Now, the 
dual tracrRNA:crRNA is engineered as a 
single guide RNA (sgRNA).
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Protospacer Adjacent Motif (PAM) 
is a sequence of a few short 2-5 base 
pairs (bp) found adjacent to one end of 
the protospacers, linked to the excision 
of protospacers and their insertion into 
CRISPR loci (Shah et al., 2013).
Plasmids carrying out a protospacer 
sequence but no PAM are resistant to 
CRISPR-Cas9 cleavage (Gasiunas et al., 
2012).
Functionality of CRISPR-Cas9
Bacteria have to deal with viruses in 
their environment. A viral infection is a 
ticking time bomb, and bacterium have 
only minutes to diffuse. In their cells, 
bacteria have CRISPR as an adaptive 
immune system that allows for the 
detection of viral DNA; it then stores 
a record of it and destroys it upon re-
exposure (Doudna and Gersbach, 2015).
The CRISPR mediate resistance is 
a multistage process that functions in 
three distinct steps that provide DNA-
encoded, RNA-mediated and sequence-
specific targeting of exogenous nucleic 
acids (Barrangou, 2015).
Adaptation 
When a virus infects a cell and 
injects its DNA, pieces of this viral 
DNA are sampled from the invasive 
by the CRISPR system. Specialized Cas 
proteins insert it into the “CRISPR loci” 
and they are acquired as novel “spacers”. 
They serve as a memory bank, enabling 
bacteria to recognize viruses and fight off 
future attacks; in a sense, the spacers in 
CRISPR are an account of the bacteria’s 
battlefield wins. Spacer acquisition is the 
first step of immunization (Barrangou, 
2015). These bits of viral DNA (spacers) 
serve as a record of infection over time 
to the viruses they have been exposed 
to. Moreover, these bits are passed on to 
the cell’s progeny (offspring), resulting 
in the protection from viruses not only 
in one generation, as Blake Wiedenheft 
referred to the CRISPR loci as a genetic 
vaccination card (Doudna and Gersbach, 
2015).
Expression
After inserting the spacers, the 
CRISPR array is transcribed and 
processed to make precursor-CRISPR 
RNAs (precrRNA) an exact replicate of 
the viral DNA. The maturation of the 
precrRNA to the crRNA requires the 
presence of a trans-activating crRNA 
(tracrRNA) co-processed by RNAS III. 
The final product is a crRNA with the 
size of a spacer-repeat unit (Sinan Al-
Attar, 2011). 
Interference
Through sequence homology, the 
dual tracrRNA:crRNA guides the 
Cas9 endonuclease. The recognition 
of invader nucleic acids then is done 
by complimentarily to the crRNA. The 
guide RNAs direct the Cas for specific 
targeting, cleavage and degradation of 
complementary nucleic acids (Barrangou, 
2015). It searches the DNA in the cell, 
and when matching sites are found, 
the complex (tracrRNA:crRNA:Cas9) 
associates with the DNA and allows Cas 
the cleaver to cut up the viral DNA by 
making a double-stranded (ds) break into 
the DNA helix and stopping the virus 
from replicating (Doudna and Gersbach, 
2015). 
On a repeat encounter with a virus, a 
bacterium can produce a stretch of RNA 
that matches the viral sequence, using the 
material in its spacer archive (Doudna 
and Gersbach, 2015).
Finally, there is a built-in safety 
mechanism, ensuring that Cas9 does 
not cut just anywhere in a genome. 
Short DNA sequences known as PAMs 
“protospacer adjacent motifs” serve as 
tags and sit adjacent to the target DNA 
sequence (Sander and Joung, 2014). They 
are essential for cleavage of the target 
DNA during the interference stage. If 
the Cas9 complex does not see a PAM 
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next to its target DNA sequence, it will 
not cut. This is a strategy CRISPR uses to 
distinguish self from non-self sequences, 
and that is the reason why Cas9 does 
not attack the CRISPR region in bacteria. 
Known Cas9 proteins will target only ds 
DNA sequences followed by a 3′ PAM 
sequence specific to the Cas9 of interest. 
Cas9 rapidly dissociates from DNA that 
does not contain the appropriate PAM 
sequence, whereas it binds for a longer 
duration at sites containing a PAM 
sequence, with the dwell time depending 
on the degree of complementarity 
between the guide RNA and the adjacent 
DNA. Once Cas9 has found a target site 
with the appropriate PAM, it triggers 
DNA unwinding from the PAM-proximal 
end to the PAM-distal end of the target 
site (Chen and Doudna, 2017) (Figure 2).
Scientists have aimed to understand 
the activity of cas9 and how they 
could harness its function as a genetic 
engineering technology to offer 
opportunities to do things that have not 
been previously possible. They found 
that it can be programmed to recognize 
particular DNA sequences and make 
a break at that site, and this activity is 
now used in genome engineering. That 
allowed scientists to perform very precise 
changes in the DNA at the site where 
the break was introduced (Doudna and 
Gersbach, 2015).
The reason why the CRISPR system 
can be used for genome engineering is 
that cells have the ability to detect and 
repair broken DNA (Eastman and Barry, 
1992), so when a plant or an animal cell 
detects a ds break in its DNA, it fixes it 
either by pasting together the ends of the 
broken DNA or it can repair the break by 
integrating a new piece of DNA at the site 
of the cut. Therefore, CRISPR is the way to 
introduce ds breaks into DNA at precise 
sites and by that we can trigger cells to 
repair those breaks either by disruption or 
incorporation of new genetic information 
(Doudna and Charpentier, 2014).
Genome engineering using CRISPR
CRISPR/Cas technology has emerged 
as the most popular tool for the precise 
alteration of the genomes of diverse 
species and different organism models. 
CRISPR/Cas9 system has taken the 
world of genome editing by storm in 
recent years, making it one of the hottest 
technology breakthroughs. Its popularity 
as a tool for altering genomes is due 
to the ability of Cas9 protein to cause 
double-stranded (ds) breaks in DNA after 
binding with short guide RNA molecules, 
which can be produced with dramatically 
less effort and expense than required for 
production of transcription activators, 
like effector nucleases (TALEN) and 
zinc-finger nucleases (ZFN). This system 
has been exploited in many species 
from prokaryotes to higher animals, 
including human cells, and the literature 
has shown increasing sophistication and 
ease of CRISPR/Cas9 and a wider range 
of species for which it is applicable. This 
technology is poised to solve several 
complex molecular biology issues 
currently faced in life science research. 
The invention of single guide RNA 
(sgRNA) by fusing crRNA and tracrRNA 
was an important breakthrough in this 
Figure 2. CRISPR–Cas immune systems 
CRISPR-encoded immunization and interference 
(Barrangou, 2015)
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field because it simplified the task of 
programming Cas9 to create breaks at 
specific DNA sites in vitro. Following 
this advance, this technology has been 
adopted for genome engineering in cells 
and different model systems 
The first step towards gene 
alteration is precise generation of 
single- or double-stranded breaks (SSB 
or DSB) in the genome. Cas9/sgRNA 
complexes can generate accurate breaks 
in the genomes of bacteria, yeast, 
plants and animals. CRISPR-Cas9 is the 
latest inclusion in the genome editing 
toolbox that already contains ZFNs and 
TALENs (Figure 3). 
The CRISPR/Cas9 system is currently 
the most desirable tool for genome 
engineering for several reasons. Cas9 
is programmed by readily engineered 
sgRNAs. The ease of CRISPR/Cas9 
use has opened new prospects for 
studying functional genomics of diverse 
organisms in a more precise manner 
with less effort when compared to other 
techniques like TALENs and ZFN. The 
variety of applications is growing at a 
rapid pace, including different types of 
knock-outs at single-gene or genome-
wide scale, knockings, activating and 
inhibitory Cas9 versions, visualization 
and even biochemical tools (Ceasar et 
al., 2016).
Generating a knockout using CRISPR
Knockout: Permanently disrupts 
gene function in a particular cell type or 
organism without a specific preferred 
mutation. 
Cas nucleases enable efficient and 
precise genetic modifications by in-
ducing targeted DNA double-strand 
breaks (DSBs) that stimulate the cellular 
DNA repair mechanisms, including er-
ror-prone non-homologous end joining 
(NHEJ) and homology-directed repair 
(HDR). The Cas9:gRNA complex binds 
to the target DNA to cleave the target 
DNA from 3’ to 5’. Then the Cas9 un-
dergoes a conformational change that 
positions the nuclease domains (RuvC 
and HNH) to cleave opposite strands of 
the target DNA that results in a ds break. 
This break in the DNA incites repair 
pathways, the efficient but error prone 
NHEJ or the less efficient but high-fidel-
ity HDR. The NHEJ is the most active 
repair mechanism that causes small nu-
cleotide insertions/deletions at ds break 
sites. Diverse arrays of mutations ap-
pear that causing amino acid insertion/
deletion/frameshift mutation that leads 
to premature stop codons of the target 
genes. The ideal result is a loss-of-func-
tion mutation within the targeted gene 
resulting in the knockout of the pheno-
type (Chen et al., 2015).
Figure 3. Evolution and structure of S. pyogenes Cas 9 (Doudna and Charpentier, 2014)
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Enhancing specificity with Nickases
Cas 9 generates ds breaks through 
the combined activity of the two 
nuclease domains RuvC and HNH. 
Casnickase is another advantage of 
CRISPR that can be converted to a 
nickase that creates single-stranded (ss) 
breaks by retaining only one nuclease 
domain and generating a DNA nick 
rather than a ds break. Either of the 
two endonuclease domains of Cas9, 
HNH and RuvC can be mutated to form 
nickases. That transforms the Cas9 
complex into a strand-specific nicking 
endonuclease (Gasiunas et al., 2012).
Activation or repression of target 
genes using CRISPR 
Repress (knockdown): reduce 
expression of particular gene(s) without 
permanently modifying the genome. 
Activate (CRISPRa): increase expression 
of an endogenous gene(s) without 
permanently modifying the genome.
RuvC and HNH domains can be ren-
dered inactive by point mutations, result-
ing in a nuclease dead Cas9 (dCas9 lack-
ing endonuclease activity) molecule that 
cannot cleave target DNA. The dCas9 
molecule retains the activity to bind to 
target DNA based on the gRNA targeting 
sequence. This system is called CRISPR 
interference (CRISPRi). Early experi-
ments demonstrated that targeting dCas9 
to transcription start sites was sufficient 
to repress transcription by blocking in-
itiation. dCas can also be tagged with 
transcriptional repressors or activators 
(Gilbert et al., 2013), and targeting these 
dCas9 fusion proteins to the promoter 
region (the section of DNA that controls 
the initiation of RNA transcription) re-
sults in rebust transcriptional repression 
or activation (it can upregulate endoge-
nous expression in human cells (Cheng 
et al., 2013), of downstream target genes 
(towards the 3’ end). The simplest dCas9-
based activators and repressors, consist of 
dCas9 fused directly to a single transcrip-
tional activator or repressor. Importantly, 
unlike the genome modifications induced 
by Cas9 or Cas9 nickase, dCas9-mediated 
gene activation or repression is reversi-
ble, since it does not permanently modify 
the genomic DNA (Qi et al., 2013).
CRISPR base editing without double-
strand breaks 
Base editing is a different approach to 
genome editing that enables the direct, 
programmable, targeted point mutations 
without inducing ds breaks by the 
conversion of a C:G base pair to a T:A 
base pair.
CRISPR base editors fuse Cas9 nickase 
or dCas9 to a cytidine déaminase. Base 
editors can convert cytidine to uridine 
within a small single-stranded DNA 
bubble at a guide RNA-specified locus 
near the PAM site. Base excision repair 
(BER) is the cell’s primary response 
to G:U mismatches, creating a C->T 
change (or G->A on the opposite strand) 
conversion in mammalian and plant 
cells. In addition, new base editors have 
been engineered to convert adenosine to 
inosine, which is treated like guanosine 
by the cell, creating an efficient and 
permanent A->G (or T->C) change on the 
opposite strand (Rees et al., 2017).
Epigenetic modification using CRISPR
Epigenetics can have several 
meanings. To Conrad Waddington, it was 
the study of epigenesis or how genotypes 
give rise to heritable phenotypes changes 
without altering the DNA sequence 
(Waddington, 1957). 
Cas enzymes can be fused to epige-
netic modifiers to create programmable 
epigenome engineering tools that could 
be used to precisely control cell phe-
notype or the relationship between the 
epigenome and transcriptional control. 
Like CRISPR activators and repressors, 
these tools alter gene expression without 
inducing a ds break. However, they are 
much more specific for particular chro-
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matin and DNA modifications, allowing 
researchers to isolate the effects of a sin-
gle epigenetic mark. Another potential 
advantage of CRISPR epigenetic tools is 
their persistence and inheritance. CRIS-
PR activators and repressors are thought 
to be reversible once the effector is inacti-
vated/removed from the system. In con-
trast, epigenetic modifiers may be more 
frequently inherited by daughter cells 
(Hilton et al., 2015). 
Visualize genomic loci using 
fluorophores
The fluorescence labelling of 
endogenous genomic DNA by CRISPR 
using a dCas9 has greatly simplified 
the study of the spatial organization of 
the genome in live cells, with numerous 
advantages over other techniques, 
including the simplicity of programming 
to target a wide array of deferent genomic 
sequences, even detecting multiple 
genomic loci. This method offers a unique 
detecting of the chromatin dynamics in 
living cells (Ma et al., 2015).
Multiplex genome engineering with 
CRISPR
CRISPR cas9 allows for simultaneous 
targeting of multiple genomic loci. This 
multiplexing feature uses multiple 
guide RNA sequences that can be 
encoded into a single CRISPR array to 
enable simultaneous editing of several 
sites within the mammalian genome, 
demonstrating easy programmability 
and wide applicability of the RNA-
guided nuclease technology.
The ability to carry out multiplex 
genome editing in mammalian cells 
enables powerful applications across 
basic science, biotechnology, and 
medicine (Cong et al., 2013).
RNA targeting 
In some bacteria, type VI CRISPR 
systems recognize single-stranded RNA 
(ssRNA) rather than dsDNA. RNA-
guided RNA-targeting type VI CRISPR 
is capable of highly efficient and specific 
RNA knockdown and degradation in 
mammalian cells. Type VI CRISPR-
Cas systems contain the programmable 
single-effector RNA-guided ribonuclease 
Cas13. Similar to Cas9, Cas13 can be 
converted to and RNA-binding protein 
through mutation of its catalytic domain 
(Cox et al., 2017).
Gene Drive
Gene drives are a particularly pow-
erful application of CRISPR technolo-
gy. They are genetic elements that in-
sert themselves into target sites lacking 
that element, converting heterozygous 
alleles to homozygous alleles within 
an organism by allowing CRISPR on 
one chromosome to copy itself to its 
partner in every generation. In organ-
isms that support sexual reproduction, 
gene drives enable non-Mendelian 
inheritance of alleles that can spread 
throughout a population. Usually, a 
genetic change in one organism takes a 
long time to spread through a popula-
tion. That is because a mutation carried 
on one of a pair of chromosomes is in-
herited by only half the offspring. But a 
gene drive allows a mutation made so 
that nearly all offspring will inherit the 
change. This spread can be rapid for spe-
cies with short reproductive generation 
times and it can quickly sweep an edited 
gene through a population. This means 
that it will speed through a population 
exponentially faster than normal. A mu-
tation engineered into a mosquito could 
spread through a large population with-
in a season if that mutation reduced the 
number of offspring a mosquito pro-
duced, then the population could be 
wiped out, along with any malaria par-
asites it is carrying. The work is at an 
early stage, but such a technique could 
be used to wipe out disease-carrying 
mosquitoes or ticks, eliminate invasive 
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plants or eradicate herbicide resistance 
(Komor et al., 2016) (Figure 4).
CRISPR applications
CRISPR is incredibly powerful. It 
has already brought a revolution to the 
day-to-day life in most laboratories, 
according to molecular biologist Jason 
Sheltzer. Programmable DNA cleavage 
using CRISPR–Cas9 enables efficient, 
site-specific genome engineering in 
single cells and whole organisms. It has 
been used in various ways, to alleviate 
genetic disorders in animals and is 
likely to be employed soon in the clinic 
to treat human diseases (Barrangou and 
Doudna, 2016). Of course, humans are not 
the only species with a genome. CRISPR 
has applications in animals and plants, 
from disabling parasites to improving 
the crop yields.  Here, we take a look at 




Figure 5 shows the cancer therapeutics 
arising from the CRISPR system as cited 
by multiple authors.
HIV
HIV still infects more than 35 
million people worldwide according 
to the Global Health Observatory data 
(updated November 2017). Not only does 
the virus infect the very immune cells in 
the body that attack viruses, but it is also 
a notorious mutator. Currently, highly 
active antiretroviral therapy (HAART) 
is able to suppress HIV infection below 
detectable levels in HIV patients. 
However, HAART is limited in its high 
Figure 4. Overview of possible experimental designs of CRISPR/Cas9 (Ceasar et al., 2016)
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cost, patient compliance, side effects 
from long‐term therapy, and emergence 
of drug resistance. Most of all, it does 
not cure HIV infection. Therefore, there 
is a continuous need to develop more 
effective therapeutics and cure strategies 
for HIV infection. Researchers now 
are using CRISPR to snip the virus from 
the cell it was infecting, shutting down the 
virus’s ability to replicate. The first use of 
the CRISPR technique to eradicate the 
HIV virus was in 2017, demonstrating a 
way to eliminate HIV from infected cells, 
resulted in reduced viral RNA expression 
and successful proviral excision. One 
of techniques used was inhibiting the 
gene coding sequences which resulted 
in a strong inhibition of HIV-1 by Cas9/
gRNA. This inhibition was obtained 
due to the deletions introduced into the 
viral DNA due to Cas9 cleavage in the 
cytoplasm and in the nucleus (Yin et al., 
2018).
Cystic Fibrosis
Cystic fibrosis is a progressive, genetic 
disease originating from mutations 
in the cystic fibrosis transmembrane 
conductance regulator (CFTR) in the 
gastrointestinal and pulmonary tract. 
Mutations in the CFTR gene disable 
the CFTR protein, an ion channel 
Figure 5. Cancer therapeutics arising from the CRISPR system (Stella et al., 2018)
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regulating epithelial fluid transport. 
Loss-of-function alleles lead to an 
accumulation of a thick and sticky mucus 
in the gastrointestinal and pulmonary 
tract, causing a number of symptoms such 
as difficulties in breathing and recurrent 
infections. In the lungs, the mucus clogs 
the airways and traps germs, like bacteria, 
leading to infections, inflammation, 
respiratory failure, and other 
complications (Savić and Schwank, 2015). 
It was recently shown that the CFTR 
gene can be corrected using CRISPR-
Cas9. The obtained results were possible 
by targeting the CFTR gene in cultured 
intestinal stem cells isolated from a cystic 
fibrosis patient (Schwank et al., 2013).
Huntington disease
This is a fatal genetic neurodegener-
ative disorder that causes nerves in the 
brain to deteriorate over time. The con-
dition results from a faulty gene that be-
comes larger than normal and produces 
a larger-than-normal form of a protein 
called huntingtin. The elongated protein 
is cut into smaller, toxic fragments that 
bind together and accumulate in neu-
rons, disrupting the normal functions 
of these cells. This process particularly 
affects regions of the brain that help co-
ordinate movement and control think-
ing and emotions. The dysfunction and 
eventual death of neurons in these areas 
of the brain underlie the signs and symp-
toms of Huntington disease. Although 
suppressing the expression of mutant 
HTT (mHTT) has been explored as a 
therapeutic strategy to treat Hunting-
ton’s disease (Shin et al., 2016). Consid-
erable efforts have gone into developing 
allele-specific suppression of mHTT ex-
pression. Researchers reported that they 
have reversed the disease by permanent 
suppression of endogenous mHTT ex-
pression in lab mice engineered to have 
a human mutant huntingtin gene in place 
of a mouse huntingtin gene. CRISPR/
Cas9-mediated inactivation was effec-
tively used to snip out part of the mutant 
huntingtin gene that produces the toxic 
bits, resulting in the evacuation of HTT 
aggregates and attenuating early neuro-
pathology. The reduction of mHTT ex-
pression in neuron cells in adult mice did 
not affect viability, but alleviated motor 
deficits. This study suggested that CRIS-
PR/Cas9-mediated gene editing could be 
used to efficiently and permanently elim-
inate the gene expansion-mediated neu-
ronal toxicity in the adult brain and the 
obtained results showed the potential of 
CRISPR to help fight this condition (Yang 
et al., 2017).
CRISPR and COVID-19
Coronaviruses are a large family of 
viruses which may cause diseases in an-
imals or humans.  In humans, multiple 
coronaviruses are known to cause res-
piratory infections ranging from the com-
mon cold to more severe diseases such 
as Middle East Respiratory Syndrome 
(MERS) and Severe Acute Respiratory 
Syndrome (SARS). For the third time in 
as many decades, a zoonotic coronavirus 
has crossed species to infect human pop-
ulations. This new virus and disease were 
unknown before the outbreak began in 
Wuhan, China in persons exposed to a 
seafood or wet market, in December 2019. 
At 9 a.m. on 7 January 2020, the virus was 
identified as a novel coronavirus and offi-
cially named by the WHO as 2019-nCoV, 
the novel 2019 coronavirus. COVID-19 is 
now a pandemic affecting many coun-
tries globally (WHO, 2020a).
The information provided by the 
Chinese public health, clinical and 
scientific communities facilitated the 
recognition of the disease. Like outbreaks 
caused by two other pathogenic human 
respiratory coronaviruses (SARS) and 
(MERS), 2019-nCoV causes respiratory 
disease that is often severe. As of 24 
January 2020, there were more than 800 
reported cases, with a mortality rate of 
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3%. Globally, as of 4:03pm CEST on 30 
June 2020, 10,185,374 cases of COVID-19 
were confirmed, including 503,862 deaths 
reported to WHO (WHO, 2020b).
After sequencing the viral genome, 
the information provided showed that 
it is 75 to 80% identical to the SARS and 
related to numerous bat coronaviruses. 
It can be spread in the same cells that 
attract the SARS and MERS viruses, 
though notably, 2019-nCoV grows better 
in primary human airway epithelial cells, 
unlike SARS or MERS (Perlman, 2020).
The structure of COVID-19
Coronaviruses are enveloped, 
non-segmented, positive-sense single-
stranded RNA virus genomes. It is the 
largest known viral RNA genome with a 
size ranging from 26 to 32 kilobases. The 
virion has a nucleocapsid composed of 
genomic RNA and phosphorylated nu-
cleocapsid (N) protein, which is covered 
with phospholipid bilayers and orna-
mented by two different types of spike 
proteins: the spike glycoprotein trimmer 
(S) that can be found in all CoVs, and the 
hemagglutinin-esterase (HE) present in 
some CoVs. The membrane (M) protein 
(a type III transmembrane glycoprotein) 
and the envelope (E) protein are located 
among the S proteins in the virus enve-
lope. CoVs were given their name based 
on the characteristic crown-like appear-
ance. The structure of the CoV virion is 
shown in Figure 6 (Li et al., 2020).
Authorizing the use of the CRISPR 
diagnostic tool during the pandemic 
The recent outbreak of the novel 
coronavirus COVID-19 can be diagnosed 
using qPCR, but the exhausted stock 
of reagents and equipment has slowed 
disease detection in some areas. To 
reduce the shortage and help increasing 
the testing, the U.S. Food and Drug 
Administration granted its first-ever 
use authorization for the gene-editing 
technology CRISPR on 7 May 2020. The kit 
was granted approval under ‘emergency 
use’ provisions, and should help to 
ease testing backlogs in the country. 
Average testing has reached nearly 
250,000 tests per day, causing shortages 
in some places. This Greenlighted corona 
diagnostic test, developed by Sherlock 
Biosciences (Cambridge, Massachusetts, 
USA) is the first authorized use of CRISPR 
technology for an infectious disease test. 
(Guglielmi, 2020).
The Sherlock CRISPR SARS-CoV-2 
Kit is a CRISPR-based SHERLOCK 
(Specific High sensitivity Enzymatic 
Reporter unLOCKing) diagnostic test. 
It works by programming the CRISPR 
machinery to detect a snippet of the 
SARS-CoV-2 genetic material (DNA or 
RNA) in samples as is used for qRT-PCR 
assays (in upper respiratory specimens, 
such as nasal swabs, and broncho-
alveolar lavage specimens, such as from 
fluid in the lungs), from individuals 
suspected of COVID-19. If viral genetic 
material is found, a CRISPR enzyme 
generates a fluorescent glow. The test can 
return results in about an hour using a 
dipstick(Guglielmi, 2020).
The SHERLOCK COVID-19 detection 
protocol works in three steps, starting 
from nucleic acid extraction as used for 
qRT-PCR tests:Figure 6. Coronavirus particle (Li, 2020)
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• Step 1: (25 min incubation) 
isothermal amplification of the 
extracted nucleic acid sample 
using a commercially available 
recombinase polymerase 
amplification (RPA) kit.
• Step 2: (30 min incubation) 
detection of pre-amplified viral 
RNA sequence using Cas13.
• Step 3: (2 min incubation) visual 
read out of the detection result 
by eye using a commercially-
available paper dipstick (Zhang et 
al., 2020).
In addition to the diagnosing tool, 
CRISPR can be used as a therapeutic 
to fight COVID-19. By activating and 
inactivating the different genes in our 
cells we can better understand how the 
coronavirus infects cells, this way can 
lead to discovering a drug to cure the 




One of the most common causes 
of childhood blindness is a condition 
called Leber congenital amaurosis (LCA), 
which affects about 2 to 3 per 100,000 
newborns. LCA is a group of inherited 
retinal diseases causing blindness or 
severe vision loss in early childhood. 
The condition is caused by mutations 
that lead to the degeneration and/or 
dysfunction of photoreceptors, the cells 
in the retina that make vision possible. 
Photoreceptors capture light, converting 
it to electrical signals which are sent 
to the back of the brain to create the 
images we see. Mutations in one of more 
than two dozen genes can cause LCA 
(Perrault et al., 2004). A study explored 
the potential of CRISPR/Cas9-mediated 
gene editing to correct the mutation, and 
found that the use of the CRISPR system 
could efficiently correct the mutation 
by deletion of the mutant genes. These 
researchers used the CRISPR-Cas 
strategy as a treatment and they noticed 
a remarkable reduction in the number 
of mutant cells. These results showed 
the therapeutic potential of CRISPR-Cas 
strategies in treating patients with LCA 
(Ruan et al., 2017).
Duchenne Muscular dystrophy
Duchenne muscular dystrophy 
(DMD) is a debilitating condition that 
develops because of a mutation in of 
the longest genes in the body that codes 
for the dystrophin protein. Because of 
the mutation in the dystrophin gene, 
the body does not make a functional 
form of the protein dystrophin, which is 
essential for muscle fibre health and for 
the integrity of muscle cell membranes 
of striated muscles. Over time, the 
lack of this protein causes progressive 
muscle degeneration and weakness. 
There is no effective treatment for this 
disease. Numerous approaches to rescue 
dystrophin expression in DMD have been 
attempted. However, these approaches 
cannot correct DMD mutations or 
permanently restore dystrophin 
expression (Pichavant et al., 2011). 
In April 2017, a team of researchers 
used CRISPR to find ways to fight 
Duchenne muscular dystrophy. They 
had used a variation of the CRISPR 
tool, called CRISPR-Cpf1 (CRISPR 
from Prevotella and Francisella) to 
correct the mutation that causes 
Duchenne muscular dystrophy. They 
fixed the gene in human cells growing 
in lab dishes and in mice carrying the 
defective gene by deletion of some of 
the Exon in that mutated gene. They 
showed that Cpf1 provides a robust and 
efficient RNA-guided genome editing 
system that can be used to permanently 
correct DMD mutations by different 
strategies, thereby restoring dystrophin 
expression and preventing progression 
of the disease. These findings showed the 
efficiency of Cpf1-mediated correction 
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of genetic mutations in human cells and 
an animal disease model and represent 
a significant step toward therapeutic 
translation of gene editing for correction 
of DMD (Zhang et al., 2017).
Fanconi Anaemia
Fanconi Anaemia (FA) is a rare 
potentially life threatening autosomal 
recessive disorder characterized by 
progressive pancytopenia, multiple 
congenital anomalies with multiple 
type of cancer risk. It is classified into 
the chromosomal instability syndromes 
(Ataxia telangiectasia, Bloom syndrome 
and Werner syndrome). Chromosomal 
instability syndromes are groups of 
disorders due to the defects in DNA 
repair, increased risk of cancer, and 
other phenotypic changes. FA is 
also classified into another group of 
syndromes, inherited bone marrow 
failure syndromes by its haematological 
abnormalities (Ahammad et al., 2017). 
The main malformations concern the 
extremities, rachis, skin, kidneys, urinary 
tract and ear, nose and throat. Advances 
in molecular biology have made it 
possible to identify 15 genes involved, 
whose mutation is responsible for 
haematological damage and increased 
risk of neoplasms (Hammoud et al., 
2020).
Cas9-mediated genome editing has 
been used to correct the mutations in 
this disease where some researchers 
employed fibroblasts derived from 
a patient with Fanconi anaemia as a 
model to test the ability of the CRISPR/
Cas9 nuclease system to mediate gene 
correction. They showed that the Cas9 
nuclease and nickase each resulted in 
gene correction, but the nickase, because 
of its ability to preferentially mediate 
homology-directed repair, resulted in 
a higher frequency of corrected genes 
(Osborn et al., 2015).
These studies collectively demon-
strate significant progress toward devel-
oping treatments for genetic diseases and 
even potential cures (Komor et al., 2016).
Life improvement
Agricultural applications
Just as CRISPR can be used to modify 
the genomes of humans and animals, 
in 2013, its application in plants was 
successfully achieved. This breakthrough 
has opened up many new opportunities 
for researchers, including the opportunity 
to gain a better understanding of plant 
biological systems (Barrangou and 
Doudna, 2016).
The use of CRISPR/Cas systems 
covers various applications, from biotic 
stress tolerance to abiotic stress tolerance, 
and also includes the achievements 
of improved yield performance, 
biofortification and enhancement of 
plant quality by reducing disease in 
some crops, while making others more 
robust. The most important group of 
target applications relates to yield traits 
followed by the achievement of biotic 
or abiotic stress tolerance. Biotic stress 
tolerance includes induced tolerance to 
viral, fungal and bacterial diseases. As 
for abiotic stress tolerance, the two main 
objectives are to achieve herbicide and 
natural environmental stress tolerances. 
Environmental stress includes cold, 
salt, drought and nitrogen stress. All 
of these trait improvements are related 
to economic and agronomic challenges 
faced by farmers as pathogens, and 
environmental conditions are important 
threats that need to be dealt with in 
agriculture. Furthermore, plant breeders 
are continually trying to increase yield 
performances. The most studied crop 
is rice (Oryza sativa) followed by other 
major crops: maize (Zea mays), tomato (S. 
lycopersicum), potato (Solanumtuberosum), 
barley (Hordeumvulgare) and wheat 
(Triticumaestivum). 
Humans have been improving the 
yield and disease resistance of crops and 
to ameliorate the quality and quantity of 
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nutrition for hundreds of years through 
traditional agricultural methods based 
on lucky hits. But now scientists are 
using CRISPR to perform the genetic 
modification of food plants, which is 
known in the world of science as GMOs 
(genetically modified organisms), as 
organisms created in the laboratory using 
genetic engineering techniques. These 
techniques consist of removing one or 
more genes from the DNA of another 
organism, such as a bacterium, virus, 
animal, or plant, and “recombining” 
them into the DNA of the plant they 
want to alter. By adding these new genes, 
genetic engineers hope the plant will 
express the traits associated with the 
genes. For example, genetic engineers 
have transferred genes from a bacterium 
known as BT into the DNA of corn. BT 
genes express a protein that kills insects, 
and transferring the genes allows the corn 
to produce its own pesticide (Ricroch et 
al., 2017).
Editing human embryos
The speed at which CRISPR-based 
studies can go from hypothesis to result 
is astounding. Experiments that used to 
take months now take weeks. And since 
these experiments have been performed 
on different species, some have also 
been applies to early human embryos. 
In 2107, a report issued by the National 
Academies of Sciences and Medicine 
recommended that trials on human 
embryos can be performed, but under 
certain conditions, and altering the cells 
in embryos, eggs and sperm was ethically 
permissible provided that it was done to 
correct a disease or a disability, not to 
enhance a person’s physical appearance 
or abilities, but to prevent genetic diseases 
from being passed to future generations 
(Saey, 2017).
More than 10,000 inherited disorders 
have been identified, affecting millions 
of people worldwide. Often there are 
no cures for these diseases. Correcting 
disease-causing genetic defects in human 
zygotes was previously unthinkable 
because the efficiency would be too low 
to be of any practical value. CRISPR/
Cas9 offers, for the first time, a tangible 
potential to allow for the correction of 
genetic defects (Tang et al., 2017). Among 
these diseases are autosomal dominant 
mutations, where inheritance of a single 
copy of a defective gene can result in 
clinical symptoms. Genes in which 
dominant mutations manifest as late-
onset adult disorders include MYBPC3, 
in which a mutation causes hypertrophic 
cardiomyopathy (HCM). Because of their 
delayed manifestation, these mutations 
escape natural selection and are often 
transmitted to the next generation. HCM 
is a myocardial disease characterized by 
left ventricular hypertrophy, myofibrillar 
disarray and myocardial stiffness; it has 
an estimated prevalence of 1:500 in adults 
and manifests clinically with heart failure. 
HCM is the most common cause of 
sudden death in otherwise healthy young 
athletes. HCM, while not a uniformly 
fatal condition, has a tremendous 
impact on the lives of individuals, 
including physiological (heart failure 
and arrhythmias), psychological (limited 
activity and fear of sudden death), 
and genealogical concerns. MYBPC3 
mutations account for approximately 40% 
of all genetic defects causing HCM, and 
are also responsible for a large fraction 
of other inherited cardiomyopathies, 
including dilated cardiomyopathy 
and left ventricular non-compaction. 
MYBPC3 encodes the thick filament-
associated cardiac myosin-binding 
protein C (cMyBP-C), a signalling node 
in cardiac myocytes that contributes to 
the maintenance of sarcomeric structure 
and regulation of both contraction and 
relaxation. Recent developments in 
precise genome-editing techniques and 
their successful applications in animal 
models have provided an option for 
correcting human germline mutations. 
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In particular, CRISPR–Cas9 where it 
was used in different division phases in 
a zygote carrying the previous MYBPC3 
mutation. The injection of CRISPR-
Cas9 during S-phase resulted in mosaic 
embryos consisting of non-targeted 
mutant, targeted NHEJ-repaired and 
targeted HDR-repaired blastomeres 
(Figure 7). These trials confirmed the 
efficiency, accuracy and safety of the 
CRISPR-Cas9 mediated-gene correction, 
suggesting that it has the potential to 
be used for the correction of heritable 
mutations in human embryos. However, 
much remains to be considered before 
clinical applications, including the 
reproducibility of the technique with 
other heterozygous mutations (Ma et al., 
2017).
Conclusions
CRISPR, this scientific breakthrough, 
has the ability to eliminate diseases, solve 
world hunger, and provide unlimited 
clean energy. It has potentially given us 
direct access to the source code of life 
and at the same time has given a great 
amount of hope to billions of people. 
The technology’s promising ability to 
deliver is a major reason why so many 
investors are spending millions of dollars 
on it. In fact, the sector CRISPR belongs 
to is experiencing something of a ‘gold 
rush’ due to massive investments, not to 
mention that about 80% of rare diseases 
are caused by faulty genes, as stated by 
the Rare Diseases Organization. These 
figures alone show what a huge impact 
the technology would have in our lives 
if used appropriately and for the right 
reasons. 
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Grupirane pravilno razmaknute kratke 
ponavljajuće palindromske sekvence 
(CRISPR)/CRISPR-povezani sustav (Cas) 
je sustav koji osigurava imunost većine 
prokariotskih organizama na napade virusa 
i drugih stranih tijela. CRISPR sustavi se 
sastoje od bjelančevine nalik škarama naziva 
Cas9 i genetskog GPS vodiča „vodičke RNK“. 
Međutim, istraživači su preorijentirali i 
prenamijenili iskonski imunosni sustav za 
preciznu manipulaciju genomom u većini 
organizama uvodeći dvolančane lomove 
na DNK na određenim lokacijama genoma 
radi uvođenja specifičnih izmjena DNK. 
Od njegova otkrića CRISPR ima sve više 
primjena; od onemogućavanja parazita do 
ispravljanja mutacija i poboljšavanja prinosa 
u poljoprivredi. Ovo istraživanje provedeno 
je da bi poslužilo kao vodič za CRISPR 
tehnologiju, od povijesti njegova otkrića 
do najnovijih saznanja. Nadamo se da će 
ova studija osigurati općeniti pregled ove 
tehnologije koja mijenja živote, a i inspirirati 
znanstvenike da nastave istraživanja s 
CRISPR-om, za bolji život.
Ključne riječi: CRISPR/Cas 9, DNK, RNK, 
genetski inženjering, virus
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